The following is a summary of "Epigenetic-modification associated hnRNPA3 acts as a prognostic biomarker and promotes malignant progression of HCC," published in the April 2025 issue of BMC Cancer by ...

Hepatocellular carcinoma (HCC) represents about 90% of all cases of liver cancer and has a poor prognosis, with a 5-year survival rate of about 18%. Previous findings had shown that RNA ...

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in ...

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

Liver cancer, particularly hepatocellular carcinoma (HCC), has become a major health concern in Uganda. The Uganda Cancer ...

Bayer and Vividion Therapeutics to present latest research on their advancing oncology portfolio at AACR 2025 annual meeting: Berlin, Germany Wednesday, April 23, 2025, 10:00 Hrs ...

The week marked several FDA approvals for drugs and devices, plus data continues to show tarlatamab’s benefit in small cell lung cancer.

Bergen, Norway, April 23, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces that it has raised NOK62 ...

Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114. See why I rate ...

Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C) for hepatocellular carcinoma (HCC). The data will ...